Clinical, histological, and molecular features of gliomas in adults with neurofibromatosis type 1
Neuro-Oncology · 2023
DOI: 10.1093/neuonc/noad033 ↗Kurz gefasst
Fachartikel in der Zeitschrift Neuro-Oncology, 2023. Verfasst von Carlos G Romo und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurology, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA. Hauptthemen laut MEDLINE: Neurofibromatosis 1, Glioma, Astrocytoma, Brain Neoplasms. Die Arbeit wurde bisher 39-mal zitiert (Crossref) und nennt 39 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS, National Institutes of Health, National Cancer Institute.
Abstract (Originalsprache)
Background
People with NF1 have an increased prevalence of central nervous system malignancy. However, little is known about the clinical course or pathologic features of NF1-associated gliomas in adults, limiting clinical care and research.
Methods
Adults (≥18 years) with NF1 and histologically confirmed non-optic pathway gliomas (non-OPGs) at Johns Hopkins Hospital, Memorial Sloan Kettering Cancer Center, and Washington University presenting between 1990 and 2020 were identified. Retrospective data were collated, and pathology was reviewed centrally.
Results
Forty-five patients, comprising 23 females (51%), met eligibility criteria, with a median of age 37 (18–68 years) and performance status of 80% (30%–100%). Tissue was available for 35 patients. Diagnoses included infiltrating (low-grade) astrocytoma (9), glioblastoma (7), high-grade astrocytoma with piloid features (4), pilocytic astrocytoma (4), high-grade astrocytoma (3), WHO diagnosis not reached (4) and one each of gliosarcoma, ganglioglioma, embryonal tumor, and diffuse midline glioma. Seventy-one percent of tumors were midline and underwent biopsy only. All 27 tumors evaluated were IDH1-wild-type, independent of histology. In the 10 cases with molecular testing, the most common genetic variants were NF1, EGFR, ATRX, CDKN2A/B, TP53, TERT, and MSH2/3 mutation. While the treatments provided varied, the median overall survival was 24 months [2–267 months] across all ages, and 38.5 [18–109] months in individuals with grade 1–2 gliomas.
Conclusions
Non-OPGs in adults with NF1, including low-grade tumors, often have an aggressive clinical course, indicating a need to better understand the pathobiology of these NF1-associated gliomas.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Neurology, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
- Departments of Neurology and Pathology, Memorial Sloan Kettering Cancer Center, New York, New York, USA.
- Departments of Neurology and Pathology, Washington University School of Medicine, St. Louis, Missouri, USA.
- Department of Pathology, University of California Los Angeles, Los Angeles, California, USA.
- Department of Pathology, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
ORCID-Profile: Carlos G Romo, Sonika Dahiya, Jaishri O Blakeley
Förderung
- NCI NIH HHS
- National Institutes of Health
- National Cancer Institute
Zitieren
APA
Romo, C. G., Piotrowski, A. F., Campian, J. L., Diarte, J., Rodriguez, F. J., Bale, T. A., Dahiya, S., Gutmann, D. H., Lucas, C. G., Prichett, L., Mellinghoff, I., & Blakeley, J. O. (2023). Clinical, histological, and molecular features of gliomas in adults with neurofibromatosis type 1. Neuro-Oncology. https://doi.org/10.1093/neuonc/noad033
Vancouver
Romo CG, Piotrowski AF, Campian JL, Diarte J, Rodriguez FJ, Bale TA, et al. Clinical, histological, and molecular features of gliomas in adults with neurofibromatosis type 1. Neuro-Oncology. 2023. doi:10.1093/neuonc/noad033
BibTeX
@article{Romo2023,
author = {Romo, Carlos G and Piotrowski, Anna F and Campian, Jian L and Diarte, Jose and Rodriguez, Fausto J and Bale, Tejus A and Dahiya, Sonika and Gutmann, David H and Lucas, Calixto-Hope G and Prichett, Laura and Mellinghoff, Ingo and Blakeley, Jaishri O},
title = {Clinical, histological, and molecular features of gliomas in adults with neurofibromatosis type 1},
journal = {Neuro-Oncology},
year = {2023},
doi = {10.1093/neuonc/noad033}
}
EUVIMED